cyrilzakka/clinical-trials huggingface dataset:
Effects and Mechanism of Pretreatment With Dexmedetomidine to Etomidate Induce Myoclonus

By observing the difference of plasma homovanillic acid concentrations and brain electrical consciousness monitoring Narcotrend index, study the possible mechanism of influencing Etomidate induced myoclonus with Dexmedetomidine pretreatment during general anesthesia induction period.


Eligibility Criteria:
Inclusion Criteria:

* Sign the informed consent
* American Society of Anesthesiologists (ASA)classification:class I\~II;undergoing elective surgery patients
* Aged between 18 and 55, 49-67 kg weight
* Body Mass Index（BMI）： 20-30 kg/m2
* Did not use any analgesic or sedatives drugs within 24 h pre-operation

Exclusion Criteria:

* Recently patients undergoing sedative drugs and antidepressant treatment
* Serious vision, hearing impairment or other reasons can not communicate
* Serious neurological disease, pregnancy, diseases of the cardiovascular system；
* BMI is Less than the standard 80% or higher than the standard 120%
A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111

The objective of the study is to evaluate the safety of bilateral, sequential sub-retinal administration of a single dose of BIIB111 in adult male participants with Choroideremia (CHM).

This study was previously posted by NightstaRx Ltd. In October 2020, sponsorship of the trial was transferred to Biogen.

Eligibility Criteria:
Key Inclusion Criteria:

1. Are willing and able to give informed consent for participation in the study to have both eyes treated.
2. Have documentation of a genetically-confirmed diagnosis of CHM.
3. Have active disease clinically visible within the macular region of both eyes.
4. Have a BCVA of ≥34 ETDRS letters (20/200 or better Snellen acuity) in both eyes, or in the untreated eye, if the other eye was previously treated with BIIB111\*

   \*If previously treated with BIIB111 in an antecedent study, participants may be eligible for participation following Sponsor approval.
5. For participants who received treatment with BIIB111 in an antecedent study, have biological samples available to complete an adequate immunology profile.

Key Exclusion Criteria:

1. Have a history of amblyopia or inflammatory disorder in either eye.
2. Are unwilling to use barrier contraception methods or abstain from sexual intercourse for a period of 3 months following treatment with BIIB111 in either eye.
3. Have had previous intraocular surgery performed within 3 months of the Screening Visit in either eye.
4. Have any other significant ocular or non-ocular disease/disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the results of the study or the participant's ability to participate in the study. This includes but is not limited to a potential participants:

   * with a contraindication to oral corticosteroid (e.g., prednisolone/prednisone)
   * with clinically significant cataract in either eye
   * who, in the clinical opinion of the Investigator, is not an appropriate candidate for sub-retinal surgery.
5. Have participated in another research study involving an investigational product in the past 12 weeks or received a gene/cell-based therapy at any time previously, except if treated within an antecedent study with BIIB111.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032

The purpose of this study is to assess the effects of hepatic impairment on the multiple dose pharmacokinetics of BMS-650032.


Eligibility Criteria:
Inclusion Criteria:

* Male and female subjects aged 18 to 70, with hepatic impairment conforming to Child-Pugh class A,B or C
* Each matched control subjects determined to be healthy

Exclusion Criteria:

* History of esophageal and gastric bleeding within the past 6 months
* Primarily cholestatic liver disease
* Active alcoholic hepatitis
* Stable encephalopathy of ≥Stage 2
* Presence of severe ascites or edema
* Presence of hepatopulmonary or hepatorenal syndrome
* Positive for HIV
* Positive for HCV, unless HCV RNA is undetectable
Epidemiological Study of Quality of Life in Osteopathy

Aim of this study is to evaluate the effectiveness of osteopathy in changing quality of life in a large sample of naive patients undergoing osteopathic manipulative treatment.


Eligibility Criteria:
Inclusion Criteria:

* older than 18 years old
* affected by muscle-skeletal disorder

Exclusion Criteria:

* younger than 18 years old
* OMT undertaken during the last 12 months
* Any manual therapy received during the last 12 months
Medication Adherence and Use of Inhaler Devices in Patients With Asthma or COPD

This study aims to evaluate the impact of a pharmacist-led intervention programme on medication adherence and use of inhaler devices on clinical outcomes of patients with asthma and COPD attending a tertiary health facility in Nigeria.

Medication non-adherence in asthma and COPD patients have been established to be very high, and along-side poor knowledge of proper use of inhaler devices, results in suboptimal disease control among these patients. Studies evaluating the impact of a comprehensive intervention on medication adherence and inhaler usage on disease control are scare in developing countries. This study was a prospective single-blind quasi-randomized-controlled study among asthma and COPD patients attending the chest out-patient clinic of the University College Hospital, Ibadan. The baseline questionnaire was administered to consenting patients to explore demographic and specific clinical characteristics, knowledge of the disease, current medications, medication adherence, knowledge of use of metered dose (MDIs) and diskus inhalers, and asthma/COPD control status using the asthma control test (ACT) and COPD assessment test (CAT) scales. Subsequently, patients were assigned into intervention or control groups using odd or even number assignation. Patients in the intervention group were followed up for two months via face to face interviews, short message services, and phone calls at one-weekly intervals, so as to provide education and counseling to resolve the identified gaps during the baseline interaction. Descriptive statistics were used to summarize the data, while chi-square, t-test, Fishers exact test and Wilcoxon-signed ranked tests were used as appropriate to test for associations at p \< 0.05.

Eligibility Criteria:
Inclusion Criteria:

Patients 18 years of age and older with a primary diagnosis of asthma or COPD by a physician who are willing to complete the study and have telephone access

Exclusion Criteria:

All non-consenting patients and patients who are not on any medications at any point in the study
Ipsihand Device Use in Stroke Patients to Assess Functional Motor Outcomes

This study aims to evaluate the impact of the Neurolutions Upper Extremity Rehabilitation System, known as IpsiHand, on improving functional motor control for post-stroke patients with hemiparesis. The Neurolutions System is a brain-computer interface (BCI) comprised of a robotic orthosis, worn on the hand and wrist, and operated by the patient's brain waves which are measured by EEG electrodes. The system also utilizes a tablet interface to provide therapy instructions to the patient.

Participants will complete 12 weeks of home therapy with the Neurolutions IpsiHand System. Outcomes will be based on a comparison of the patient's baseline measurements to post-therapy assessments.

Eligibility Criteria:
Inclusion Criteria:

* 6-months or more post stroke
* Presentation of upper extremity hemiparesis or hemiplegia
* Participants must english speaking
* Demonstrate intact cognition to provide informed consent
* Botox injections are allowed, and must continue regimen at regular intervals throughout the study

Exclusion Criteria -

* Not active in another clinical study
* Not receiving formal therapy for the upper extremity
* No use of other modalities or technologies to the upper extremity
* Cognitive Impairment: Short Blessed Test Score 9 or above
* Significant Spasticity: Modified Ashworth Scale score 3 or more at the elbow
* Significant Hemispatial Neglect: Mesulam Cancellation Test 3 or more unilaterally
* Insufficient Strength: Motricity Index score for shoulder abduction 18 - Any contractors of the affected upper extremity that would not allow the IpsiHand robotic exoskeleton to be worn comfortably and/or safely for device use
The SINCERE Intervention to Address COVID-19 Health Disparities

The goal of this real world efficacy study is to understand the benefit of universal social needs screening, community-based service referrals, and telephonic follow-up as a scalable strategy for preventing COVID-19 transmission, and for addressing the secondary health effects of the social, behavioral, and economic changes following the COVID-19 pandemic. With statewide community service providers, existing health information technology, and piloted methods, we seek to determine the effectiveness of universal social needs screening and community service referrals - the SINCERE intervention - in improving health outcomes of COVID-19 vulnerable and socioeconomically disadvantaged populations and whether intensive follow-up and collaborative goal-setting helps overcome barriers to community service use by patients seen in the emergency department and seeking COVID testing at community-based and mobile clinic locations.


Eligibility Criteria:
Inclusion Criteria:

* Adult (\> 17 years)
* English or Spanish speaking
* Completed the referral process at the UHealth ED, one of the COVID-19 testing sites or the Primary Children's ED and indicated both social needs and willingness to receive service low- and no-cost referrals from the United Way 211 community referral service
* Able to be reached by phone during the intervention OR able to complete surveys sent by text or email

Exclusion Criteria:

* Those unable to communicate verbally
* Those living in nursing facilities, or those who are not otherwise responsible for self-care
Evaluation of an Ultra-speed Picosecond Laser for Treating Tattoos

The investigators developed an ultra-speed picosecond laser (20ps) with a 20gHz repetition rate that provide very promising results in vitro and in ex vivo skin to remove skin tattoos.

The aim of this study is to evaluate the efficacy and tolerance of a new ultra-speed picosecond laser and to compare it to a nanosecond laser for treating black tattoos.

In a first phase of the study 10 patients with black tattoos will be treated with increasing fluencies of the picosecond laser to the optimal parameters in terms of efficacy and tolerance.

In a second phase, 10 additional subjects with black tattoos will be treated after central randomization on half of the tattoo with the picosecond laser (with the parameters determined in the first phase) and the other half treated with a nanosecond laser.


Eligibility Criteria:
Inclusion Criteria:

* Black tattoos with surface between 10 and 100 cm²
* Skin type I to VI

Exclusion Criteria:

* Childbearing age women
* Active dermatosis located on the tattoo
* Personal history of hypertrophic scars or keloids
* Pigmentary or vascular lesions located on the tattoo
* Subject taking oral steroid or retinoid or have any risk of delayed healing problems
* Acquired or hereditary conditions that could leead to a delayed healing
* Allergy to xylocaine, prilocaine or lidocaine
Study of the Effects of Iron Levels on the Lungs at High Altitude

The study hypothesis is that body iron levels are important in determining the increase in lung blood pressure that occurs in response to low oxygen levels. The purpose of this study is to determine whether this is true at high altitude, where oxygen levels are low.

Pulmonary hypertensive disorders frequently complicate hypoxic lung disease and worsen patient survival. Hypoxia-induced pulmonary hypertension is also a major cause of morbidity at high altitude. Hypoxia causes pulmonary hypertension through hypoxic pulmonary vasoconstriction and vascular remodelling. These processes are thought to be regulated at least in part by the hypoxia-inducible factor (HIF) family of transcription factors, which coordinate intracellular responses to hypoxia throughout the body.

HIF is regulated through a cellular degradation process that requires iron as an obligate cofactor. In cultured cells HIF degradation is inhibited by reduction in iron (by chelation with desferrioxamine) and potentiated by iron supplementation. In humans, we have recently shown that, in laboratory experiments lasting 8 hours, acute iron supplementation blunts the pulmonary vascular response to hypoxia, while acute iron chelation with desferrioxamine enhances the response.

This suggests that iron may also affect the pulmonary artery pressure response to hypoxia over longer time periods. The purpose of this study is to investigate this link between iron and the pulmonary artery pressure response to hypoxia, through a study conducted at high altitude allowing concurrent exposure of larger numbers of participants to environmental hypoxia. We wish to explore the extent and the time-course of the effect of iron on pulmonary artery pressure. Cerro de Pascu (4,340 m) in Peru provides the unique ability to make rapid transitions from sea level to high altitude (6-8 hours by road), together with the requisite research facilities. Also, one part of this study involves recruitment of patients with chronic mountain sickness, of whom there are many living in Cerro de Pasco.

Eligibility Criteria:
SLR ARM

Inclusion Criteria:

* sea level natives of lowland ancestry
* generally in good health
* detectable tricuspid regurgitation on echocardiography

Exclusion Criteria:

* any significant medical problem
* known susceptibility to high altitude pulmonary or cerebral oedema
* taking medications or iron supplements

CMS ARM

Inclusion Criteria:

* diagnosis of chronic mountain sickness
* no recent venesection therapy (within 1 year)
* detectable tricuspid regurgitation on echocardiography

Exclusion Criteria:

* any other significant medical problem
Therapy of Pain Syndromes According to McGill's Method in Physiotherapy

The goal of this study is to determine the applicability of McGill ́s method to patients with diagnoses, collectively referred to as Vertebrogenic Algic syndrome, by comparing the measured data of proband with different diagnosis locations Vertebrogenic Algic syndrome in the Czech Republic.

This is a pilot experimental research involving 10 probands diagnosed with Vertebrogenic Algic syndrome in the cervical spine, 10 probands diagnosed with Vertebrogenic Algic syndrome in the thoracic spine and 10 probands diagnosed with Vertebrogenic Algic syndrome in the lumbar spine. Each participant undergo a kinesiological examination according to the McGill ́s principles together with an SF-36 questionnaire. Measured values are compared and provided a basis for testing the hypotheses. The study uses methods of research, observation, querying and comparison of collected data.

Eligibility Criteria:
Inclusion Criteria:

* cervical pain syndrome
* thoracic pain syndrome
* lumbar pain syndrome

Exclusion Criteria:

* red falgs
Get With the Guidelines-Stroke Registry

Get With The Guidelines-Stroke is a program for improving the quality of care for patients hospitalized with stroke by promoting consistent adherence to the latest evidence-based clinical practice guidelines.

Get With The Guidelines®-Stroke is an in-hospital program for improving stroke care by promoting consistent adherence to the latest scientific treatment guidelines. Since its initiation in 2003, 2,637 hospitals have entered 3,892,063 patient records into the Get With The Guidelines-Stroke database. Numerous published studies demonstrate the program's success in achieving measurable patient outcome improvements.

Achievement measures tracked through the Get With The Guidelines®-Stroke:

* IV rT-PA arrive by 3.5 hour, treat by 4.5hour
* Early antithrombotics
* VTE prophylaxis
* Antithrombotics at or by discharge
* Anticoagulation for Afib/Aflutter at or by discharge
* Smoking cessation at or by discharge
* Intensive Statin Therapy

Quality measures tracked through the Get With The Guidelines®-Stroke:

* Dysphagia screen
* Time to intravenous thrombolytic therapy-60 min
* NIHSS reported
* Stroke education at or by discharge
* Rehabilitation considered at or by discharge
* LDL Documented

Additional measures collected by Get With The Guidelines®-Stroke can be viewed at: https://www.heart.org/en/professional/quality-improvement/get-with-the-guidelines/get-with-the-guidelines-stroke/get-with-the-guidelines-stroke-patient-management-tool

Eligibility Criteria:
Inclusion Criteria:

* Patients presented with a diagnosis of Ischemic stroke or transient ischemic attack, Subarachnoid hemorrhage, Intracerebral hemorrhage, or Stroke not otherwise specified to the hosptials.

Exclusion Criteria:

* Patients who do not have a diagnosis of Ischemic stroke or transient ischemic attack, Subarachnoid hemorrhage, Intracerebral hemorrhage, or Stroke not otherwise specified.
* Patients under age of 18
Gut Microbiota, SCFAs and Glucolipid Metabolism in Pregnant Women With Abnormal Fetal Size and Their Newborns

Abnormal fetal size includes fetal growth restriction and fetal macrosomia. Onset is closely related to maternal nutrition metabolism. The specific correlation and mechanism is unclear, and there are no effective measures for early diagnosis and treatment. Previous study found that maternal gut microbiota participates in the material metabolism throughout the pregnancy. Insulin sensitivity in pregnant women, and intrauterine environment under abnormal blood glucose and lipid metabolism are important for the gut microbiota of newborns and even they grow up. However, changes in gut microbiota are the cause of the disease or the outcome is not yet clear. Short chain fatty acids (SCFAs) are produced from soluble dietary fibers in the diet by colon bacteriolysis. Studies have found that gut microbiota can regulate insulin sensitivity and glucose and lipid metabolism disorders through SCFAs. Therefore, this research group uses the gut microbiota as a new idea to studythe relationship of gut microbiota characteristics and level's change of SCFAs with glucolipid metabolism and insulin sensitivity in pregnant women with abnormal fetal size and their newborns through 16S-rRNA high-throughput sequencing, pyrosequencing, and gas chromatography-mass spectrometry, so we can reveal the role of gut microbiota in the pathogenesis of abnormal fetal size and explore targeted rational dietary adjustment and SCFAs reconstruction of gut microbiota to improve maternal and neonatal pregnancy outcomes.


Eligibility Criteria:
Inclusion Criteria:

* Singleton pregnancy
* Term pregnancy with the gestational age of 37-40 weeks

Exclusion Criteria:

* Maternal systemic diseases (hypertension disorders, immunological diseases) or pregnant complications (polyhydramnios, oligohydramnios, diabetes mellitus, intrahepatic cholestasis of pregnancy)
* Delivery before 37 weeks or after 40 weeks
* Neonates had major congenital malformations (congenital anal atresia, congenital biliary atresia, congenital heart disease)
Hemostasis in Liver Cirrhosis and Hepatocellular Cancer

Evaluating hemostasis in decompensated liver cirrhosis with novel hemostatic assays.

The rebalanced hemostasis in liver cirrhosis is vulnerable and patients are prone to both bleeding and thrombosis. There are today no gold standard for evaluating the hemostasis and we will evaluate novel methods for this.

Eligibility Criteria:
Inclusion Criteria:

* Patients with decompensated liver cirrhosis
* 18 years or older.
* Healthy individuals 18 years or older will serve as controls.

Exclusion Criteria:

* • Extrahepatic malignancy or recurrence of such within the last year.

  * Diagnosis of non-cirrhotic coagulopathy, coagulation disorder or thrombophilia prior to inclusion.
  * Diagnosis of hematological disease such as hematologic malignancies, non-cirrhotic thrombocytopenia or thrombocytosis, Polycytemia Vera, hemoglobinopathies
  * Previous liver transplantation.
  * Transfusions the last 7 days.
  * Treatment with platelet inhibitors or anticoagulant except for prophylactic dosage of LMWH. If a prophylactic dose of LMWH has been used study sampling with addition of antiFXa must be taken \>12 hours after the last injection.
Development of an Intelligent POWER Rehabilitation Cluster Machine and Its Clinical Testing and Assessment

Elderly care has become one of the most important subjects in Taiwan and "frailty syndrome" are the most common problems among the elderly. In view of this trend, Taipei Veteran Memorial Hospital imported POWER rehabilitation from Japan in 2008. While showing significant clinical benefits, investigators have found that the system still has certain limitations (e.g. high cost, requires large space, patients must commute to the center, lacks real-time objective feedback , boring routines makes staying power to motivate patients for long term rehabilitation programs.)

To overcome the above limitations, this project proposes an evidence-based rehabilitation model that accounts for actual clinical need and collaborates with our engineering team to develop a "cluster" , "wearable" and "Brain-Computer Interface System" version of POWER rehabilitation system. Combining cloud technology, investigators now introduce internet-of-things into the POWER rehabilitation procedure. The result will lower the burden of clinical support personnel, and provide an opportunity to quantify "frailty syndromes" so as to allow objective and quantitative scientific evaluation, leading to a more objective clinical diagnosis.

In addition, this project further proposes a virtual-reality (VR) system for POWER rehabilitation, as well as designs for the VR sceneries. Through the use of different animated 3D VR sceneries and interactive game design, investigators can make rehabilitation interesting and fun for the patients, motivating long-term compliance of the patients, thereby, improving the clinical outcome of POWER rehabilitation.

This project has the potential to create an innovative solution to address the current bottlenecks of our rehabilitation treatment model. Successful development of the system will offer rehabilitation clinicians more treatment options, lower the cost of supporting staff, reduce commuting cost for the patients, and elevate patient desire to comply with the treatment program. Finally, the system will not only enhance Taiwan's academic reputation in the international arena, it will also generate new commercial opportunities for Taiwan and contribute to Taiwan economic development.


Eligibility Criteria:
Inclusion Criteria:

* aged 60 to 85
* Cardiovascular Health Study (CHS) frailty criteria
* willing to sign agreement

Exclusion Criteria:

* fracture w/o healing
* severe joint injury
* acute stroke or myocardial infarction (\< 3 months)
* cardiac arrhythmia / unstable blood pressure
* disorientation or intellectual deterioration
* muscle contracture deformity
* pregnancy
DiCART TM Device for Capillary Refill Time Measurement

To estimate peripheral perfusion in shock state, international guidelines recommend the use of capillary refill time, and practitioners currently evaluates it at bedside. However its measurement is not standardized, what should explain the large observer variability reported in different studies. Hence, a device providing a standardized evaluation seems to be helpful.

The aim of the study is to evaluate diagnostic performance of such a device recently developped (DiCART TM), in healthy volunteers experiencing vascular occlusion tests to induce impaired perfusion.


Eligibility Criteria:
Inclusion Criteria:

* Healthy volunteers
* Age \> 18 years old
* Informed consent to participate

Exclusion Criteria:

* Vascular disease
* Diabetes mellitus
* Dermatosis
* Cutaneous lesion on a measurement site
* Anemia
* Pregnancy
* Cardiovascular chronic treatment
* Non affiliation to a social security regime
* Involvement in other interventional study